A Recombinant MVA-Based RSV Vaccine Induces T-Cell and Antibody Responses That Cooperate in the Protection Against RSV Infection.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 22 12 2021
accepted: 13 05 2022
entrez: 1 7 2022
pubmed: 2 7 2022
medline: 6 7 2022
Statut: epublish

Résumé

Respiratory syncytial virus (RSV) causes a respiratory disease with a potentially fatal outcome especially in infants and elderly individuals. Several vaccines failed in pivotal clinical trials, and to date, no vaccine against RSV has been licensed. We have developed an RSV vaccine based on the recombinant Modified Vaccinia Virus Ankara-BN

Identifiants

pubmed: 35774800
doi: 10.3389/fimmu.2022.841471
pmc: PMC9238321
doi:

Substances chimiques

Antibodies, Viral 0
Immunoglobulin A 0
Respiratory Syncytial Virus Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

841471

Informations de copyright

Copyright © 2022 Endt, Wollmann, Haug, Bernig, Feigl, Heiseke, Kalla, Hochrein, Suter, Chaplin and Volkmann.

Déclaration de conflit d'intérêts

KE, JH, CB, MF, MK, HH, AV, and PC are employees of Bavarian Nordic. YW and AH were employed by Bavarian Nordic at the time of conducting this study. MS is employed as a consultant at Bavarian Nordic. The authors declare that the study was funded by Bavarian Nordic. The funder was involved in the study design, collection, analysis, interpretation of data, the writing of this article, and the decision to submit it for publication.

Références

Vaccine. 2017 May 9;35(20):2617-2621
pubmed: 28410812
J Immunol. 1999 Mar 1;162(5):2521-9
pubmed: 10072491
Immunology. 1987 Sep;62(1):133-8
pubmed: 3498683
Virology. 2006 Aug 15;352(1):157-68
pubmed: 16730775
J Immunol. 1998 Dec 1;161(11):6215-22
pubmed: 9834108
J Immunol. 1999 Mar 1;162(5):2530-7
pubmed: 10072492
J Med Virol. 1991 May;34(1):7-13
pubmed: 1885946
J Exp Med. 1988 Sep 1;168(3):1163-8
pubmed: 3262705
J Virol. 2002 Jan;76(2):560-8
pubmed: 11752147
Am J Respir Crit Care Med. 2003 Jun 15;167(12):1641-9
pubmed: 12626348
J Infect Dis. 2021 Mar 29;223(6):1062-1072
pubmed: 32726422
J Clin Invest. 1991 Sep;88(3):1026-33
pubmed: 1909350
Curr Opin Virol. 2013 Aug;3(4):468-74
pubmed: 23806514
J Virol. 2015 Feb;89(3):1889-99
pubmed: 25428875
J Immunol. 2015 Oct 1;195(7):3301-10
pubmed: 26290604
J Virol. 1995 Nov;69(11):6658-64
pubmed: 7474075
J Infect Dis. 2015 Dec 1;212(11):1719-25
pubmed: 25977264
Nature. 1987 Jul 2-8;328(6125):77-9
pubmed: 2955227
J Immunol. 2002 Apr 1;168(7):3493-501
pubmed: 11907110
PLoS Negl Trop Dis. 2014 Nov 20;8(11):e3300
pubmed: 25412267
PLoS Pathog. 2015 Mar 04;11(3):e1004675
pubmed: 25738498
Immun Ageing. 2012 Oct 02;9(1):21
pubmed: 23031690
Exp Eye Res. 2015 Jun;135:93-101
pubmed: 25864785
Vaccine. 2020 Mar 4;38(11):2608-2619
pubmed: 32057576
Am J Pathol. 2007 Dec;171(6):1944-51
pubmed: 17991711
Nature. 1986 Apr 3-9;320(6061):449-51
pubmed: 2938014
Vaccine. 2017 Jan 11;35(3):469-480
pubmed: 27908639
Antivir Ther. 2005;10(2):285-300
pubmed: 15865223
J Infect Dis. 1991 Apr;163(4):693-8
pubmed: 2010624
J Infect Dis. 2017 Dec 12;216(11):1362-1370
pubmed: 29029260
J Virol. 1991 Sep;65(9):4936-42
pubmed: 1908028
Nature. 1997 Dec 18-25;390(6661):687-90
pubmed: 9414161
Vaccine. 2012 Jan 11;30(3):597-606
pubmed: 22120195
J Virol. 1991 Aug;65(8):4494-7
pubmed: 2072460
Curr Protoc Immunol. 2016 Apr 01;113:4.1.1-4.1.9
pubmed: 27038463
Vaccine. 2009 Dec 9;27(52):7442-50
pubmed: 19539582
Eur J Immunol. 2003 Apr;33(4):950-61
pubmed: 12672061
J Immunol. 2010 May 1;184(9):4585-6
pubmed: 20410494
Infect Immun. 2015 Jul;83(7):2785-95
pubmed: 25916989
Nature. 1990 Apr 19;344(6268):742-6
pubmed: 2139497
J Immunol. 1987 Sep 15;139(6):2032-7
pubmed: 3114383
J Med Virol. 2002 May;67(1):92-100
pubmed: 11920822
PLoS One. 2010 Jul 19;5(7):e11580
pubmed: 20657846
Am J Respir Crit Care Med. 2015 May 1;191(9):1040-9
pubmed: 25730467
Am J Respir Crit Care Med. 2010 Nov 15;182(10):1305-14
pubmed: 20622030
N Engl J Med. 1986 Jul 10;315(2):77-81
pubmed: 3724802
J Exp Med. 1991 Oct 1;174(4):875-80
pubmed: 1919440
J Immunol. 1993 Aug 15;151(4):2032-40
pubmed: 8345194

Auteurs

Kathrin Endt (K)

Bavarian Nordic GmbH, Martinsried, Germany.

Yvonne Wollmann (Y)

Bavarian Nordic GmbH, Martinsried, Germany.

Jana Haug (J)

Bavarian Nordic GmbH, Martinsried, Germany.

Constanze Bernig (C)

Bavarian Nordic GmbH, Martinsried, Germany.

Markus Feigl (M)

Bavarian Nordic GmbH, Martinsried, Germany.

Alexander Heiseke (A)

Bavarian Nordic GmbH, Martinsried, Germany.

Markus Kalla (M)

Bavarian Nordic GmbH, Martinsried, Germany.

Hubertus Hochrein (H)

Bavarian Nordic GmbH, Martinsried, Germany.

Mark Suter (M)

University of Zürich, Dekanat Vetsuisse-Fakultät Immunology, Zurich, Switzerland.

Paul Chaplin (P)

Bavarian Nordic GmbH, Martinsried, Germany.

Ariane Volkmann (A)

Bavarian Nordic GmbH, Martinsried, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH